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Hemophilia A is a hereditary X-linked disorder caused by a deficiency in
coagulation factor VIII (FVIII) or functional defect of the gene, resulting in
lifelong bleeding disorder. Hemophilia A is observed at a frequency of 1-2 in
10,000 males and characterized by bleeding into soft tissues, muscles and weight-
bearing joints.
1 The clinical severity of hemophilia and plasma FVIII level are
closely related with mild (more than 5%), moderate (1-5%) or severe (less than
1%) phenotypes, and symptomatic patients usually have less than 5% of FVIII
levels.
2 The current standard therapy is intravenous injection of plasma-derived
FVIII concentrates or recombinant FVIII protein. Maintenance of circulating
FVIII levels higher than 5% of the normal FVIII concentration may significantly
improve the clinical symptoms.
3 Even though the replacement therapy has been
standard treatment for hemophilia, high cost, unpredictable shortages of
recombinant FVIII products and risk of blood-borne virus transmission have been
major disadvantages.
4 Another problem of replacement treatment is the
development of the FVIII neutralizing antibodies in 20-30% of hemophilia
patients, rendering further substitution ineffective.
5 Therefore, gene therapy is
being explored as the next generation therapy for hemophilia patients. Gene
therapy is considered suitable for hemophilia treatment because of several
reasons. First, hemophilia gene therapy can easily correct this abnormality.
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Purpose: This study was designed to investigate whether transduction of lentiviral vectors (LV) carrying human
coagulation factor VIII (hFVIII) cDNA into skeletal muscle could increase circulating hFVIII concentrations.
Materials and Methods: A LV containing bacterial LacZ gene as a control or human FVIII gene was intra-
muscularly administered into the thigh muscle of 5 weeks old Sparague-Dawley rats. The plasma human FVIII
concentration and neutralizing anti-FVIII antibodies were measured for up to 12 weeks in these experimental
animals. Results: The plasma human FVIII levels in the rats injected with LV carrying FVIII cDNA peaked at
post-injection 1st week (5.19 ± 0.14 ng/mL vs. 0.21 ± 0.05 ng/mL in control rats , p < 0.05). Elevated hFVIII
concentrations were maintained for 4 weeks (2.52 ± 0.83 ng/mL vs. 0.17 ± 0.08 ng/mL in control rats, p < 0.05)
after a single intramuscular injection. In the Bethesda assay, neutralizing antibodies for FVIII protein were detected
only in FVIII-LV injected rats by the 10th week, but not in control rats.  Conclusion: This study suggested that a
single administration of an advanced generation LV carrying the human FVIII cDNA resulted in elevation of FVIII
level in immune competent rats, and that this gene transfer approach to the skeletal muscle could be an effective
tool in treatment of hemophilia A.
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INTRODUCTIONSecond, wide therapeutic window with low FVIII concen-
tration in 2-5% of normal level will be sufficient to correct
the severe phenotype. Furthermore, the site-specific expre-
ssion is not required to achieve the therapeutic goals.
6-8
The development of gene therapy for hemophilia A has
been explored by using ex vivo and in vivo gene delivery
strategies. Ex vivo gene therapy has the advantage of
avoiding the systemic administration of viral vectors.
Although therapeutic levels of FVIII could be detected in
plasma, the limited survival of implanted cells can lead to
gradual decline of gene expression and surgical procedure
on ex vivo protocol could be undesirable in hemophilia
patients. In vivo gene therapy provides cost-effective
treatment compapred to most of the ex vivo protocols. In
general, viral vector mediated gene transfer is more
efficient than non-viral gene transfer.
9 Currently, the
vectors used for in vivo FVIII gene transfer include adeno-
viral vectors, adeno-associated viral vectors, retroviral
vectors and lentiviral vectors. Each vector has its own
advantages and drawbacks. Lentiviral-based vectors
present several attractive features for FVIII gene therapy.
The vector transduces the interesting genes into the
proliferating and non-proliferating cells at similar effi-
ciencies and mediates stable integration, resulting in
sustained expression.
10-13 In this study, we evaluated the
possibility of hFVIII increase by transduction of lentiviral
vectors (LV) into skeletal muscle cells. 
Lentiviral vectors plasmids  
The vector plasmids were all derivatives of the pRRL-
RRE-cPPT-EF1α-X-PRE-SIN. The transfer plasmid
pRRL-RRE-cPPT-EF1α-hFVIII-PRE-SIN containing the
human B-domain deleted coagulation FVIII cDNA, driven
by EF1α promoter, and pRRL-RRE-cPPT-PGK-LacZ-
PRE-SIN containing nuclear localized lacZ, driven by the
PGK promoter, were cloned using standard techniques.
The packaging construct, pCMV∆R8.74, and the envelope
plasmid, pMD.G, have been previously described.
14 The
rev-expressing plasmid, pRSV-REV, and the packaging
plasmid, pCMV.gag.pol.RRE.bpA, were provided by Dr.
Frank Park (Medical College of Wisconsin, Milwaukee,
WI, USA).
Lentiviral production and assays
The vesicular stomatitis virus (VSV)-G pseudotyped lenti-
viral vectors were generated as previously described in our
lab.
15 In brief, transient calcium phosphate transfection of
293T cells was performed using the following amounts of
DNA: 10 µg transfer plasmid, 6.5 µg packaging plasmid, 5
µg rev-expressing plasmid and 3.5 µg envelope plasmid.
Chloroquine (25 µM) was added to the media prior to
transfection. Media were replaced 12 hours after transfec-
tion, harvested after further 36 hours of incubations, and
then filtered and concentrated by ultracentrifugation. The
concentrated viral pellet was resuspended in PBS contain-
ing 10 µg/mL polybrene. For the titer of the LV stocks with
lacZ gene, serial dilution of concentrated virus was used to
infect 5×10
5 Hela cells in a 6-well plate in the presence of
polybrene (8 µg/mL). For the LV containing the human B-
domain depleted FVIII gene, the titer of the vector prepara-
tion was determined by enzyme-linked immunosorbent
assay (ELISA) for the p24 Gag antigen concentration
(Alliance; Dupont-NEN).
In vivo gene-transfer protocols 
Five weeks old Sprague-Dawley male rats were used in
the experiments. Lentiviral vectors containing Lac Z gene
as a control or FVIII gene at a dose of 1.5×10
7 infectious
unit (15 ug of p24 Gag antigen) were intramuscularly
injected with 10 µg/mL of polybrene into the thigh muscle. 
X-gal staining of tissue sections 
Four weeks after virus injection, the injected skeletal
muscle, liver, spleen, and lungs were harvested and snap
frozen using O.C.T embedding medium on dry ice. Sections
were made at 10 um thickness, fixed in 0.1% glutaral-
dehyde, washed in PBS, and subsequently stained in 5-
bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal,
Invitrogen, Carlsbad, CA, USA) solution overnight. Then,
the sections were rinsed in PBS, mounted, studied under a
microscope, and photographed.
Measurement of plasma human FVIII concentration 
Blood sample was obtained by tail vein catheterization at
post-injection 0, 1st, 2nd, 3rd, 4th week and then every 2
weeks up to 12 weeks. Blood samples were transferred
into the Eppendorf tubes containing 20% sodium citrate.
Plasma was isolated by centrifugation and stored at -80˚C
for determination of FVIII activity. The plasma concentra-
tion of human FVIII was measured by ELISA as described
by the manufacturer (Affinity Biologicals, Hamilton, ON,
USA). 
Detection of anti-FVIII antibodies 
Anti-FVIII antibodies were measured by Bethesda assay
as described by the manufacturer (Stago Deficient VIII,
Asnieres, France). 
Statistical analysis 
Statistical significance was assessed by Wilcoxon rank
sum test. p < 0.05 was taken as significant. Data were ex-
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MATERIALS AND METHODSpressed as means ± standard deviation.
In vitro production of human coagulation FVIII in 
lentiviral vector-transduced Hela cells 
To determine the functionality of lentiviral vectors to
express hFVIII, Hela cells were transduced by lentiviral
vectors carrying hFVIII cDNA, incubated for 3 days and
conditioned media was harvested to measure hFVIII
concentrations. As shown in Fig. 1, hFVIII concentrations
were dose-dependently elevated, following increasing
amount of administered virus (n = 2, independent experi-
ments). 
β β-galactosidase assays 
To assess the transduction efficiency of lentivirus in the
skeletal muscle, lentiviral vector (LV) carrying bacterial
LacZ (dose of 1.5×10
7 infectious unit) was injected into the
thigh muscle. Four weeks after injection, the LV-injected
skeletal muscle, liver, lung, and spleen were harvested and
sectioned for X-gal staining. Fig. 2 shows strong, localized
X-gal-stained nuclei only in the skeletal muscle (Fig. 2A).
No X-gal-stained nuclei were found in any other organs,
including the liver (Fig. 2B), lung (Fig. 2C), or spleen (Fig.
2D). These results demonstrate that skeletal muscle could
be effective target tissue for long-term foreign gene expres-
sion. 
Plasma FVIII concentrations following LV adminis-
tration into the skeletal muscle 
After virus injection, the plasma FVIII levels of pLV-FVIII
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RESULTS
Fig. 1. In vitro production of human coagulation factor VIII in HeLa cells trans-
duced with lentiviral vectors (LV). Hela cells (5×10
5cells) were transduced with
increasing dose of lentiviral vector (ng p24 Gag antigen, which is an index of
titer) carrying the human B-domain depleted coagulation factor VIII cDNA. The
media were changed 24 hours after initial transduction, and the cells were
incubated for an additional 48 hours prior to harvesting the media for the
assessment of factor VIII concentration by enzyme-linked immunosorbent
assay (ELISA) (n = 2, independent experiments). Fig. 3.Temporal expression of plasma human factor VIII levels following lentiviral
vector administration. Plasma factor VIII levels isolated from rats which were
injected with lentiviral vector expressing human factor VIII (●, n = 4) or bacterial
lacZ (control) rats (� , n = 4) over the course of the experiment. Data are exp-
ressed as mean ±SD. *p< 0.01. 
Fig. 4. Bethesda assay for anti-human factor VIII antibody. Analysis for antibody
against human factor VIII showed that neutralizing antibodies developed in rats
injected with pLV-factor VIII after 10 weeks, but not in control rats. 
Fig. 2. X-gal staining of tissue harvested from lentiviral vector-injected rats. Four
weeks after intramuscular injection of lentivirus containing lacZ gene (1.5×10
7
infectious units), the following organs were harvested; the lentiviral vector-
injected skeletal muscle (A), liver (B), lung (C) and spleen (D). The tissues were
sectioned (10 µm) and stained with X-gal to examine the expression of lacZ in
vivo, following lentiviral vector transduction. (A) Shows definitive X-gal stained
myocytes (×400), (B-D) but no other X-gal-positive cells are detected in the
other three organs (×400). 
A
C
B
Dinjected rats (n = 4) were found to be significantly increased
up to 5.19 ± 0.14 ng/mL at post-injection 1st week (vs.
0.21 ± 0.05 ng/mL in pLV-LacZ injected rats, p < 0.05).
These elevated levels were maintained for 4 weeks (2.52 ±
0.83 ng/mL vs. 0.17 ± 0.08 ng/mL in pLV-LacZ injected
rats rats, p< 0.05) (Fig. 3). 
Presence of plasma anti-FVIII antibodies concentrations 
Since the rats used in these experiments were immune-
competent, we suspected whether the low levels of FVIII
concentrations in the pLV-FVIII injected rats after 6 weeks
were due to the production of neutralizing antibodies to
human coagulation FVIII protein. Analyses for antibody
against human FVIII showed that neutralizing antibodies
developed in pLV-FVIII rats after 10 weeks, but not in
control rats (Fig. 4). 
Data in this study showed that a single administration of an
advanced generation lentivral vector, carrying the human
B-domain deleted FVIII cDNA, into the hind limb of ske-
letal muscle of immune-competent rats resulted in effective
elevation of circulating human FVIII.
Hemophilia gene therapy requires the gene delivery
system that is efficient, safe, non-immunogenic and permits
long term FVIII expression in the circulation. Only three
lentivirus out of nine wild types of HIV gene have recently
been engineered as the new vectors to transfer genetic ma-
terial and produce functional, non-replicating viral vector.
10
The lentivirus vectors are well recognized for their ability
to transduce proliferating and non-proliferating cells at a
similar efficiency.
11 Data in the current study have shown
that the advanced generation lentiviral vectors in Hela cells,
carrying a FVIII cDNA, were capable of producing high
concentrations of active FVIII in vitro. 
The human B-domain deleted FVIII was chosen in this
study, because the B-domain structure does not require
procoagulant activity in contrast to full-length of human
FVIII cDNA which contains a domain structure of A1-A2-
B-A3-C1-C2.
16 The B-domain deleted hFVIII retains coa-
gulant activity and is secreted from cultured cells more
efficiently than with full length FVIII. Furthermore, it is less
sensitive to degradation.
17,18
The liver appears to be the appropriate primary target
organ for transduction since FVIII is naturally synthesized
in hepatocytes and hepatic sinusoidal endothelial cells.
13
Despite the fact that FVIII is synthesized in the liver, its
biologically active form can be synthesized in a variety of
tissues. Therefore, the site specific expression is not required.
Ogata, et al.
19 reported that transduction of adipocytes with
vectors carrying the human FVIII gene may be applicable
for hemophilia A gene therapy. The subcutaneous adipose
tissue is accessible for vector administrations and can safely
be resected in the event of adverse reaction. Ishiwata et al.
20
explored the possibility of increasing circulating FVIII by
tranducing adeno-associated virus (AAV) vectors into
skeletal muscles, and showed sufficient expression of
FVIII in the skeletal muscles and proven that AAV vectors
could produce FVIII in the skeletal muscles. In our study,
FVIII concentration levels were monitored throughout the
12 weeks period of time after a single injection of FVIII-
expressing LV into rat’s skeletal muscle, and the results
showed sufficient expression of circulating human FVIII.
Therefore, this gene transfer approach to the skeletal
muscle could be an effective alternative system for hemo-
philia A gene therapy. 
The major concern in vivo gene therapy for hemophilia
A is the host immune response towards the viral vector. It
would be an obstacle if multiple injections are required to
achieve long-term therapeutic FVIII levels. The level of
plasma FVIII in rat was monitored in the present study,
and we observed that the FVIII level was gradually decre-
ased from 2.52 ± 0.83 ng/mL to 0.37 ± 0.24 ng/mL at the
6th week after LV transduction, whereas anti-FVIII anti-
bodies at 0.08 Bethesda unit/mL in serum were detected
by the 10th week after vector injection. Since animals used
in this study were immune-competent, we could not rule out
the possibility of neutralizing antibodies developed against
FVIII. The present data showed that FVIII levels were
initially high (5.19 ± 0.14 ng/mL) accompanied by non-
detectable anti-FVIII antibodies. Production of neutralizing
antibodies after 6 weeks appears to be inversely correlated
with the coagulation FVIII levels in the plasma. We ob-
served that the plasma FVIII level was reduced by the 6th
week, followed by the detection of neutralizing antibodies
at the 10th week. There were 4 weeks of window period
between the appearance of neutralizing antibodies and the
reduction of plasma FVIII. It is highly possible that silenc-
ing promoter in vivo might have occurred, subsequently
leading to decrease of FVIII production, since the levels of
anti-FVIII antibodies were minimal. However, the expres-
sion of transgene with LV can last for several months.
21
Therefore, the possibility of silencing promoter seems to
be unlikely to take place in our study. To circumvent the
neutralizing antibody formation, some investigators em-
ployed tissue specific promoters instead of ubiquitous pro-
moters or immune deficient cells. Moayeri, et al.
22 reported
that therapeutic levels of FVIII were detected in the plasma
of the transplant recipients for over 6 months of time: In
this study, the recipient mice received minimally myeloa-
blative dose of total body irradiation in order to blunt the
host immune response. Kang, et al.
23 showed that intra-
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DISCUSSIONvenous administration of GP64-pseudotyped feline immu-
nodeficiency virus vector conferred sustained FVIII expres-
sion in hemophilia A mice for several months (7 months)
without developing anti-human FVIII antibodies and
further resulted in partial phenotypic correction. The use of
a liver-specific promoter and vector modifications facili-
tated hepatocyte transduction rate by approximately 20
percent. Shi, et al.
24 used the platelet-specific glycoprotein
IIb gene promoter to direct FVIII expression, and demon-
strated that the expression of FVIII in platelets has the
advantage of delivering clotting factors directly to the site
of an injury, despite the presence of FVIII inhibitory anti-
bodies. Therefore, the presence of pre-existing inhibitory
antibodies against FVIII might not be a contraindication
for such a gene transfer system. Liu, et al. 
25 used non-viral
vectors to overcome immunological problems associated
with viral vectors: They used Sleeping Beauty transposon-
based delivery to target endothelial cells for the production
of human FVIII and achieved therapeutic levels of FVIII
and phenotypic correction of bleeding disorder in the animal
model throughout 24 weeks period of time. The level of
neutralizing antibodies against FVIII protein was negligible.
To precisely understand the underlying antigen presen-
tation in immunologic mechanisms, the gene transfer
immune response and induction tolerance would be the
key for the success in hemophilia gene therapy. 
We expect that only extramuscular sites are transduced
via transport through the bloodstream. To resolve problems,
we may additionally need to perform a comparative study
using an another animal model that is genetically closer to
humans rather than rat. 
In summary, the present study showed an elevated
circulating FVIII level in rats by single administration of
advanced generation LV carrying FVIII cDNA, and sug-
gested that the gene transfer approach via skeletal muscle
could be an effective therapeutic tool for hemophilia A. 
This study was supported by a Korean Hemophilia Foun-
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